Skip to content

Gilead/Immunomedics deal lifts antibody-drug conjugate developers

September 14, 2020

Gilead Sciences’ (NASDAQ:GILD) announced $21B takeout of Immunomedics (NASDAQ:IMMU), a developer of therapeutic antibodies, including antibody-drug conjugates (ADCs), has stoked premarket action in fellow ADC players Seattle Genetics (NASDAQ:SGEN) (+9%) and Mersana Therapeutics (NASDAQ:MRSN) (+17%), both on light volume.

https://seekingalpha.com/news/3613593-gilead-immunomedics-deal-lifts-antibody-drug-conjugate-developers

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: